Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Albrecht, Lea Jessica; Dimitriou, Florentia; Grover, Piyush; Hassel, Jessica C.; Erdmann, Michael; Forschner, Andrea; Johnson, Douglas B.; Varaljai, Renata; Lodde, Georg; Placke, Jan Malte; Krefting, Frederik; Zaremba, Anne; Ugurel, Selma; Roesch, Alexander; Schulz, Carsten; Berking, Carola; Poettgen, Christoph; Menzies, Alexander M.; Long, Georgina V.; Dummer, Reinhard; Livingstone, Elisabeth; Schadendorf, Dirk; Zimmer, Lisa

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Autor(en):

Albrecht, Lea Jessica; Dimitriou, Florentia; Grover, Piyush; Hassel, Jessica C.; Erdmann, Michael; Forschner, Andrea; Johnson, Douglas B.; Varaljai, Renata; Lodde, Georg; Placke, Jan Malte; Krefting, Frederik; Zaremba, Anne; Ugurel, Selma; Roesch, Alexander; Schulz, Carsten; Berking, Carola; Poettgen, Christoph; Menzies, Alexander M.; Long, Georgina V.; Dummer, Reinhard; Livingstone, Elisabeth; Schadendorf, Dirk; Zimmer, Lisa

Tübinger Autor(en):

Forschner, Andrea Lydia

Erschienen in:

European Journal of Cancer (2024), Bd. 202, Article 113976

Verlagsangabe:

London : Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2024.113976

ISSN:

0959-8049